How Telix’s BiPASS Phase 3 Pre‑Biopsy PSMA Trial At Telix Pharmaceuticals (ASX:TLX) Has Changed Its Investment Story

On 16 January 2026, Telix Pharmaceuticals announced that the first U.S. patient had been dosed in BiPASS, a Phase 3 trial ...